GD3-mimetic peptides

Details GD3-mimetic peptides GD3-mimetic peptides

2008-03-11

2008-03-11

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S014800, C530S387500, C530S387900

Reexamination Certificate

active

07341994

ABSTRACT:
GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing the same.

REFERENCES:
patent: 5102663 (1992-04-01), Livingston et al.
patent: 6676946 (2004-01-01), Bay et al.
patent: 533 199 (1993-03-01), None
patent: 8-53366 (1996-02-01), None
patent: 8-508978 (1996-09-01), None
patent: 10-237098 (1998-09-01), None
patent: 10-237099 (1998-09-01), None
Qui et al (Hybridoma 18:103-112 (1999)).
Monzavi-Karbassi et al. (TRENDS in Biotech. 20(5):207-214 (May 2002)).
Hakomori (Adv Exp Med Biol 491:369-402 (2001)).
Willers et al (Peptides 20:1021-1026 (1999)).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138).
Lazar et al Molecular and Cellular Biology Mar 1988 vol. 8 No. 3 1247-1252).
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Stedman's Medical Dictionary 27thEd.
Popa et al., FEBS Letters 580:1398-1404, 2006.
Worley, K.C. (ref 2, submitted Aug. 4, 2000; see copy of search output, pp. 1-2).
Cerato et al. (Hybridoma 16(4):307-316 (1997).
AC078804 NCBI Blast report (pp.1-12).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Jianping Qiu et al.: “Toward the development of peptide mimotopes of carbohydrate antigens as cancer vaccines” HYBRIDOMA, vol. 18, No. 1, pp. 103-112 1999.
Soo Kie Kim et al.: “Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH” VACCINE, vol. 18, pp. 597-603 Hybridoma (1), (1999) 2000.
David A. Cheresh et al.: “Localization of gangliosides GD2and GD3in adhesion plaques and on the surface of human melanoma cells” Proc. Natl. Acad. Sci., vol. 81, pp. 5767-5771 Sep. 1984.
Meenhard Herlyn et al.: “Characteristics of cultured human melanocytes isolated from different stages of tumor progression” Cancer Research, vol. 45, pp. 5670-5676 Nov. 1985.
Alan N. Houghton et al.: “Mouse monoclonal IgG3antibody detecting GD3ganglioside: A phase I trial in patients with malignant melanoma” Proc. Natl. Acad. Sci., vol.82, p. 1242-1246 Feb. 1985.
Philip O. Livingston: “Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside—KLH conjugate vaccines” Immunological Review, vol. 145, pp. 147-163 1995.
Philip O. Livingston et al: “Carbohydrate vaccines that induce antibodies against cancer. 1 Rationale” Cancer Immunol. Immunother., vol. 45, pp. 1-45 1997.
Charlotte R. Kensil et al.: “Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex” J. Immunol., vol. 146, No. 2, pp. 431-437 Jan. 15, 1991.
Dai Ishikawa et al.: “Preparation of glycol-replica peptides” Cell Enginerring, vol. 16, No. 12, pp. 1821-1828 1997.
Jianping Qiu et al.: “Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines” HYBRIDOMA, vol. 18, No. 1, pp. 103-112 1999.
Joerg Willers et al.: “Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside” PEPTIDES, vol. 20, pp. 1021-1026 1999.
Jorg Willers, et al., “Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside”, PEPTIDES, vol. 20, No. 9, pp. 1021-1026 1999.
Dai Ishikawa, et al., “GD1α-replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis”, FEBS Letters, vol. 441, No. 1, pp. 20-24 Dec. 11, 1998.
Jamie K. Scott, et al., “Searching for peptide ligands with an epitope library”, SCIENCE, vol. 249, pp. 386-390 1990.
Thomas Kieber-Emmons, et al., “Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses”, Nature Biotechnology, vol. 17, No. 7, pp. 660-665 1999.
Friedhelm Helling, et al., “GD3 Vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines”, Cancer Research, vol. 54, pp. 197-203 Jan. 1, 1994.
M. Laura Nasi, et al. “Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside”, Melanoma Research, vol. 7, No. suppl. 2, pp. S155-S162 1997.
Philip O. Livingston, “Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines”, Immunological Reviews, No. 145, pp. 147-166 1995.
Kim et al. “Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines”, Vaccine, vol. 18, pp. 597-603 2000.

Affiliated with

Also associated with

Rating

GD3-mimetic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GD3-mimetic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GD3-mimetic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2814036